Denali Therapeutics (DNLI) Operating Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Operating Expenses data on file, last reported at $137.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $137.4 million, down 5.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $547.1 million (up 6.19% YoY), and the FY2025 annual result was $555.3 million, up 10.65% from the prior year.
• Operating Expenses steadied at $137.4 million in Q1 2026 per DNLI's latest filing, from $137.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $156.0 million in Q1 2023 and troughed at $108.6 million in Q1 2022.
• A 5-year average of $127.7 million and a median of $129.8 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 43.55% in 2023, then decreased 15.2% in 2024.
• A 5-year view of Operating Expenses shows it stood at $115.6 million in 2022, then advanced by 14.65% to $132.6 million in 2023, then fell by 2.06% to $129.8 million in 2024, then advanced by 5.79% to $137.4 million in 2025, then dropped by 0.01% to $137.4 million in 2026.
• Business Quant data shows DNLI's Operating Expenses at $137.4 million in Q1 2026, $137.4 million in Q4 2025, and $137.4 million in Q3 2025.